Chemistry:Xeligekimab
From HandWiki
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | GR1501 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Xeligekimab (GR1501) is a monoclonal antibody that neutralizes interleukin-17A;[1] it is being developed for plaque psoriasis,[2] axial spondyloarthritis,[3] and lupus nephritis.[4] It is in a Phase III trial in 2023.[5]
References
- ↑ Shan, Yunlong; Shi, Ke; Qian, Xuelong; Chang, Zhiyuan; Yang, Jiaqian; Gao, Yuan; Jin, Wei; Luo, Qiong et al. (17 September 2019). "Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A". Biochemical and Biophysical Research Communications 517 (2): 303–309. doi:10.1016/j.bbrc.2019.07.078. ISSN 1090-2104. PMID 31353088. https://pubmed.ncbi.nlm.nih.gov/31353088/.
- ↑ Dong, Wenliang; Nie, Xiaoyan; Wang, Jiaxue; Xia, Lin; Cai, Lin; Wang, Qian; Wang, Wei; Fu, Weixing et al. (1 November 2020). "Randomised, double-blind, multicentre, phase I/II dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol" (in en). BMJ Open 10 (11): e039067. doi:10.1136/bmjopen-2020-039067. ISSN 2044-6055. PMID 33234634. PMC 7689088. https://bmjopen.bmj.com/content/10/11/e039067.
- ↑ Sen, Rouhin; Caplan, Liron (1 December 2022). "Current treatment and molecular targets for axial spondyloarthritis: Evidence from randomized controlled trials". Current Opinion in Pharmacology 67: 102307. doi:10.1016/j.coph.2022.102307. ISSN 1471-4892. PMID 36335714. https://www.sciencedirect.com/science/article/abs/pii/S1471489222001345.
- ↑ "Delving into the Latest Updates on Xeligekimab with Synapse" (in en). https://synapse.patsnap.com/drug/630dc96a7158463dab2d69ca39183e6b.
- ↑ Denis, Agathe; Sztejkowski, Cédric; Arnaud, Laurent; Becker, Guillaume; Felten, Renaud (2023). "The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials". RMD Open 9 (3): e003279. doi:10.1136/rmdopen-2023-003279. ISSN 2056-5933. PMID 37507210.
 |  |
